Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1991-11-14
|
pubmed:abstractText |
In malignant hyperthermia, dantrolene, a drug assumed to possess calcium channel blocking properties, effectively suppresses supraventricular and ventricular arrhythmias. To investigate antiarrhythmic properties of dantrolene, six patients (three women and three men, age 42 +/- 18 yr) with symptomatic atrioventricular (AV)-nodal reentry tachycardia were studied. Electrocardiographic measurements included sinus cycle length, PQ-interval, width of the QRS-complex, and QT- and rate-corrected QT-interval. During the electrophysiologic study, effective refractory periods of the right atrium, AV node, right ventricle, and AV-nodal conduction intervals were determined, and AV-nodal reentry tachycardia was induced in all patients. Dantrolene was administered intravenously over a period of 15 min at doses of 1.0, 1.5, or 3.0 mg/kg in two patients each. The dosage was not further increased because of side effects at the dose of 3.0 mg/kg. After the infusion of dantrolene, the electrocardiographic measurements and electrophysiologic study were repeated. The plasma concentrations of dantrolene ranged from 1.69 to 6.61 micrograms/ml at the time of the electrophysiologic study. After dantrolene administration, the sinus cycle length shortened from 686 +/- 80 to 622 +/- 55 ms (P less than 0.05). No significant changes of any other parameter could be demonstrated after intravenous dantrolene. AV-nodal reentry tachycardia remained inducible in all patients without change of the tachycardia cycle length and without change in coupling intervals of tachycardia-inducing extrastimuli. Antiarrhythmic properties of dantrolene could not be demonstrated in patients with AV-nodal reentry tachycardia at therapeutic doses.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0003-3022
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
75
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
583-7
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:1928768-Adult,
pubmed-meshheading:1928768-Anti-Arrhythmia Agents,
pubmed-meshheading:1928768-Calcium Channel Blockers,
pubmed-meshheading:1928768-Dantrolene,
pubmed-meshheading:1928768-Female,
pubmed-meshheading:1928768-Heart Conduction System,
pubmed-meshheading:1928768-Humans,
pubmed-meshheading:1928768-Injections, Intravenous,
pubmed-meshheading:1928768-Male,
pubmed-meshheading:1928768-Malignant Hyperthermia,
pubmed-meshheading:1928768-Middle Aged,
pubmed-meshheading:1928768-Tachycardia, Atrioventricular Nodal Reentry
|
pubmed:year |
1991
|
pubmed:articleTitle |
Intravenous dantrolene does not exhibit calcium channel blocking effects on the cardiac conduction system in humans.
|
pubmed:affiliation |
Department of Anesthesiology, University Hospital, Eppendorf, Hamburg, Federal Republic of Germany.
|
pubmed:publicationType |
Journal Article
|